Clinical significance of serum p53 antibodies in oral cancer

被引:17
作者
Sainger, Rachana Narendra Singh
Shah, Manisha Hasmukhray
Desai, Amisha Anil
Shukla, Shilin Nandubhai
Shah, Pankaj Manubhai
Telang, Shaila Dattatraya
Patel, Prabhudas Shankerbhai [1 ]
机构
[1] Gujarat Canc Res Inst, Biochem Res Div, Ahmadabad 380016, Gujarat, India
[2] Maharaja Sayajirao Univ Baroda, Dept Biochem, Vadodara, India
来源
TUMORI JOURNAL | 2006年 / 92卷 / 02期
关键词
oral cancer; oral precancerous conditions; p53; antibodies; prognosis; treatment monitoring;
D O I
10.1177/030089160609200209
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Aim and background: The incidence and mortality due to oral cancer have increased worldwide. In India, the use of tobacco has been found to be the major etiological factor for the development of oral cancers. Various studies on serum p53 antibodies have suggested their clinical importance as prognostic markers in cancer. However, there is a dearth of data on serum p53 antibodies in oral cancer patients in India. The present study was carried to evaluate the clinical significance of serum p53 antibodies in oral cancer. Materials and methods: The serum p53 antibody status was analyzed by means of ELISA in 55 healthy individuals, 60 patients with oral precancerous conditions, 75 untreated oral cancer patients, and 86 follow-up blood samples of the oral cancer patients. Results: We found serum p53 antibodies in 23% of cancer patients. The frequency of p53 antibody positivity was higher in patients with lymph node metastasis, advanced disease and well-differentiated tumors. Furthermore, p53 antibody positivity strongly correlated with poor treatment outcome in cancer patients. Kaplan-Meier survival analysis showed significantly poorer disease-free survival in patients with serum p53 antibodies. Conclusion: The results of this study suggest the usefulness of serum p53 antibodies in the prognostication of oral cancer patients.
引用
收藏
页码:134 / 139
页数:6
相关论文
共 23 条
[1]  
Angelopoulou K, 1996, CANCER, V78, P2146, DOI 10.1002/(SICI)1097-0142(19961115)78:10<2146::AID-CNCR15>3.0.CO
[2]  
2-Z
[3]   Detection of the TP53 tumour suppressor gene product and p53 auto-antibodies in the ascites of women with ovarian cancer [J].
Angelopoulou, K ;
Diamandis, EP .
EUROPEAN JOURNAL OF CANCER, 1997, 33 (01) :115-121
[4]   Analysis of p53 serum antibodies in patients with head and neck squamous cell carcinoma [J].
Bourhis, J ;
Lubin, R ;
Roche, B ;
Koscielny, S ;
Bosq, J ;
Dubois, I ;
Talbot, M ;
Marandas, P ;
Schwaab, G ;
Wibault, P ;
Luboinski, B ;
Eschwege, F ;
Soussi, T .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1996, 88 (17) :1228-1233
[5]   DETECTION OF ANTIBODIES AGAINST THE CELLULAR PROTEIN P53 IN SERA FROM PATIENTS WITH BREAST-CANCER [J].
CRAWFORD, LV ;
PIM, DC ;
BULBROOK, RD .
INTERNATIONAL JOURNAL OF CANCER, 1982, 30 (04) :403-408
[6]  
Gottschlich S, 2003, ANTICANCER RES, V23, P913
[7]  
*GUJ CANC RES I, 2001, HOSP BAS CANC REG
[8]   Implications of p53 alterations and anti-p53 antibody response in head and neck squamous cell carcinomas [J].
Lavieille, JP ;
Righini, C ;
Reyt, E ;
Brambilla, C ;
Riva, C .
ORAL ONCOLOGY, 1998, 34 (02) :84-92
[9]  
Maass JD, 1997, ANTICANCER RES, V17, P2873
[10]  
Ralhan R, 1998, CLIN CANCER RES, V4, P2147